{"disease":{"id":"post-essential-thrombocythemia-myelofibrosis-post-et-mf","name":"post essential thrombocythemia myelofibrosis post et mf"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT03441113","title":"Extended Access of Momelotinib in Adults With Myelofibrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":237,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02101268","title":"Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT06343805","title":"A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Ajax Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04217993","title":"Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT03895112","title":"MPN-RC 118 AVID200 in Myelofibrosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"John Mascarenhas","has_results":false},{"nct_id":"NCT03935555","title":"Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Samus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07340138","title":"Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}